Combination therapy of CD70 and BCL-2 inhibitors for treatment of acute myeloid leukemia

The present invention relates to combination therapies, in particular for the treatment of myeloid malignancies. The combination therapy is particularly useful in methods for the treatment of acute myeloid leukemia (AML). The combination therapy comprises an antibody, or an antigen-binding fragment...

Full description

Saved in:
Bibliographic Details
Main Authors DE HAARD HANS, VAN ROMPAEY LUC, OCHSENBEIN ANDREA, LEUPIN NICOLAS, RITTER CHRISTOF, FUNG STEPHEN
Format Patent
LanguageChinese
English
Published 07.04.2023
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention relates to combination therapies, in particular for the treatment of myeloid malignancies. The combination therapy is particularly useful in methods for the treatment of acute myeloid leukemia (AML). The combination therapy comprises an antibody, or an antigen-binding fragment thereof, that binds to CD70 and a BCL-2 inhibitor, preferably vinca or a pharmaceutically acceptable salt thereof. 本发明涉及组合疗法，特别是用于治疗骨髓性恶性肿瘤的组合疗法。所述组合疗法在用于治疗急性骨髓性白血病(AML)的方法中特别有用。所述组合疗法包括与CD70结合的抗体或其抗原结合片段和BCL-2抑制剂，优选地维奈克拉或其药学上可接受的盐。
Bibliography:Application Number: CN20221104780